Novartis is proposing to the Australian Pharmaceutical Benefits Advisory Committee that Jakavi (ruxolitinib) be made available on the PBS for patients with polycythemia vera (PV).
Currently Jakavi is on the PBS for patients with myelofibrosis in certain circumstances.
The use of Jakavi by Novartis is proposed for PV patients in certain circumstances – that is, where a patient is resistant to or intolerant of hydroxycarbamide (also known as hydroxyurea or Hydrea).
The letter from Novartis to MPN AA’s Nathalie Cook and Ken Young provides further information on Novartis’ proposal. Novartis PV letter_Aug_2019
The Pharmaceutical Benefits Advisory Committee (PBAC) has opened a call for public submissions. Submissions can be made up until 9 October 2019.
If you wish to make a submission, here is the link. https://www1.health.gov.au/internet/main/publishing.nsf/Content/PBAC_online_submission_form